Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]Cu-HTE1PA-9E7.4
- Development stage
- Preclinical
- Lead developer
- Nantes Université
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[64Cu]Cu-HTE1PA-9E7.4 is a preclinical theranostic radioimmunoconjugate consisting of the rat anti-mouse CD138 (syndecan-1) monoclonal antibody (clone 9E7.4) conjugated to the monopicolinate cyclam-based chelator HTE1PA (TE1PA) and radiolabeled with the positron- and beta-emitting radionuclide copper-64 (64Cu). Developed by researchers at Nantes Université, CNRS, Inserm, and the University of Brest, this agent is designed for immuno-PET imaging and targeted radionuclide therapy (TRT) of multiple myeloma. The 9E7.4 antibody specifically targets CD138, a cell surface proteoglycan highly overexpressed on multiple myeloma cells, while the HTE1PA chelator provides high thermodynamic stability and kinetic inertness, preventing transchelation of copper-64 in vivo. Preclinical studies in murine multiple myeloma models have demonstrated high tumor uptake, excellent PET imaging contrast, and therapeutic efficacy in delaying tumor growth and extending survival.
- Other names
- 64Cu-9E7.4-p-SCN-Bn-TE1PA64Cu-HTE1PA-9E7.464Cu-TE1PA-9E7.4[64Cu]Cu-TE1PA-9E7.4
02
Targets
SDC1 (Syndecan-1)
Beyond the preview
Go deeper on [64Cu]Cu-HTE1PA-9E7.4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [64Cu]Cu-HTE1PA-9E7.4.